openPR Logo
Press release

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Pipeline Review, H2 2017

10-27-2017 01:46 PM CET | Health & Medicine

Press release from: ReportsWorldwide

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Pipeline Review, H2 2017

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Pipeline Review, H2 2017

ReportsWorldwide has announced the addition of a new report title Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Pipeline Review, H2 2017 to its growing collection of premium market research reports.

Summary
According to the recently published report 'Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H2 2017'; Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function.

The report 'Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H2 2017' outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 3 and 5 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Gastrointestinal, Dermatology, Metabolic Disorders, Respiratory and Women's Health which include indications Autoimmune Disorders, Breast Cancer, Allergies, Chronic Pain, Contact Dermatitis, Inflammatory Bowel Disease, Non-Small Cell Lung Cancer, Osteoarthritis Pain, Bladder Cancer, Cervical Cancer, Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Endometriosis, Epithelial Ovarian Cancer, Gastrointestinal Tract Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Inflammatory Pain, Lung Cancer, Osteoporosis, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Solid Tumor and Ulcerative Colitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

To Enquire about this Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=41708

Scope
- The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
- The report reviews Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/prostaglandin-e2-receptor-ep4-subtype-prostanoid-ep4-receptor-or-ptger4-pipeline-review-h2-2017

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends. Moreover, ReportsWorldwide's Research Associates have in-depth knowledge of the reports and services on offer and are ready to provide assistance.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Pipeline Review, H2 2017 here

News-ID: 790463 • Views: 249

More Releases from ReportsWorldwide

World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports. Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors. Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports. This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers: • CommScope/Airvana • Comba Telecom • Ericsson • Huawei Technologies • Nokia • SpiderCloud • ZTE Corporation This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021. To view a detailed description and Table of
UDAY’s Impact and Compatibility State wise indexing of Integrated Power Supply …
Boston, MA ReportsWorldwide has announced the addition of a new report title UDAY’s Impact and Compatibility State wise indexing of Integrated Power Supply Chain in India – 2017 to its growing collection of premium market research reports. UDAY scheme was touted as the next paladin to bail out the struggling Discoms, in order to turn them green in a time horizon of 3-4 years from 2015/16. Though was optional for the

All 5 Releases


More Releases for EP4

Canine Arthritis Market: How the Market will perform in Upcoming Years based on …
Canine arthritis is a major ailments seen in the middle aged to older dogs. Most common causes of canine arthritis include, cartilage deficits, previous injuries such as anterior cruciate ligament, poor nutrition, trauma after a car accident, penetration of joint by a sharp object, or bite, infection in the joint, stresses on the joint, disruption of cartilage, bone, synovial membranes, and ligaments that support a joint, bacteria spread through the
Canine Arthritis Market to Witness Increased Revenue Growth Owing to Rapid Incre …
Canine arthritis is a major ailments seen in the middle aged to older dogs. Most common causes of canine arthritis include, cartilage deficits, previous injuries such as anterior cruciate ligament, poor nutrition, trauma after a car accident, penetration of joint by a sharp object, or bite, infection in the joint, stresses on the joint, disruption of cartilage, bone, synovial membranes, and ligaments that support a joint, bacteria spread through the
Bio-Lubricants Market | Growth, Trends and Forecasts 2022 by Total S.A, Exxon Mo …
Global Bio-Lubricants Market – Overview With an increasing level of impetus placed on environmentally safe products, Bio Lubricants are being manufactured to address the problems associated with using other forms of lubricants. They are highly popular and are easily manufactured by the use of vegetable oils such as soya bean, coconut, canola and rapeseed etc. Market Research Future, who specializes in reports related to chemicals and materials recently stated in a
Bio-lubricants Market Share 2018 to 2022, Top Players - Total S.A, Exxon Mobil, …
Global Bio-Lubricants Market – Overview With an increasing level of impetus placed on environmentally safe products, Bio Lubricants are being manufactured to address the problems associated with using other forms of lubricants. They are highly popular and are easily manufactured by the use of vegetable oils such as soya bean, coconut, canola and rapeseed etc. Market Research Future, who specializes in reports related to chemicals and materials recently stated in a
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Pi …
ReportsWorldwide has announced the addition of a new report title Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary According to the recently published report 'Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H2 2017'; Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 11 molecules. Out of which approximately
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Pipe …
"The Report Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" According to the recently published report 'Prostaglandin E2 Receptor EP4 Subtype Pipeline Review, H2 2017'; Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 11 molecules. Out of which approximately 10